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Available online 11 July 2012Abstract Genomic integrity of human pluripotent stem cell (hPSC) lines requires routine monitoring. We report here that novel
karyotyping assay, utilizing bead-bound bacterial artificial chromosome probes, provides a fast and easy tool for detection of
chromosomal abnormalities in hPSC lines. The analysis can be performed from low amounts of DNA isolated from whole cell pools
with simple data analysis interface. The method enables routine screening of stem cell lines in a cost-efficient high-throughput
manner.
© 2012 Elsevier B.V. Open access under CC BY license.Primary human embryonic stem cell (hESC) lines, as well as
induced pluripotent stem cell (iPSC) lines, provide a valuable
resource for developmental studies, disease modeling and
development of regenerative therapies. Long term culture of
hESC is associated with the accumulation of karyotypic
abnormalities (Draper et al., 2004; Cowan et al., 2004; Baker
et al., 2007). Based on previous large scale studies on at least
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Open access under CC BY license.abnormalities in hESCs involve partial or whole gains of
chromosomes 12, 17, 20 or X (Baker et al., 2007; Laurent et
al., 2011; Taapken et al., 2011; Spits et al., 2008; Lefort et al.,
2008; The International Stem Cell Initiative et al., 2011).
Furthermore, pluripotent reprogramming, required for the
derivation of iPSC, is associated with frequent copy number
variation (Hussein et al., 2011). Thus, continuousmonitoring of
the genomic integrity of these lines is important, as genomic
alterations may change the developmental potential and
malignant capacity of the cells.
Conventional karyotyping has been most commonly used
to monitor the genomic status of the cells. The method
enables early detection of abnormalities in heterogeneous
populations. However, the analysis is usually limited to less
193High-Throughput Karyotyping of Human Pluripotent Stem Cellsthan 50 mitosis instead of the whole cell population.
Furthermore, conventional karyotyping is costly, slow and
laborious hampering the frequency of the analysis. While array
based methods enable high resolution analysis of the whole
cell population, they are also expensive, slow and require
specialized expertise for data analysis and interpretation.
Furthermore, the complexity of the array data can be difficult
to interpret, as for instance it is not clear which of the small
scale aberrations detected in hESCs have been present already
in the original blastocyst from which the cells have been
derived. For routine and frequent monitoring of the hESC and
iPSC karyotypes, fast, simple and inexpensive method would
be highly beneficial for laboratories producing, maintaining
and utilizing hESCs or iPSCs.
KaryoLite™ BoBs™, developed by PerkinElmer, is a novel
improved method for fast and easy molecular karyotyping
based on BACs-on-Beads™ technology (Vialard et al., 2011).
The assay measures DNA copy numbers at the chromosome
arm resolution utilizing bacterial artificial chromosome
(BAC) probes immobilized onto color-encoded polystyrene
microspheres distinguishable by a Luminex fluorometer. The
KaryoLite™ BoBs™ consists of 90 beads, each of which is a
composite of three different neighboring BACs based on the
available Human Genome Build. The probes are targeted to
proximal and terminal regions of each chromosome arm of
metacentric and sub-metacentric chromosomes and q-arms of
acrocentric chromosomes. As previous studies have indicated
that the most common karyotypic abnormalities in hESCs
involve gains of whole chromosomes or telomeric regions of
chromosomes, it is expected that the frequent and recurrent
abnormalities are covered by the probes included in the
KaryoLite™ BoBs™ (Baker et al., 2007; Laurent et al., 2011;
Taapken et al., 2011).
To compare the novel method to conventional G-banding
and array based methods, we reanalyzed seven different hESC
lines from our previous detailed genomic analysis (Table 1) by
Narva et al. (2010). Most of these samples had been previously
analyzed with both G-banding and Affymetrix high resolution
SNP6.0 arrays. In addition, new samples of H9 line, with normal
(H9p35 and H9p38) or abnormal (H9p99 and H9p112) karyotype
were included in the analysis. This panel of samples represents
karyotypes ranging from normal to most commonly observedTable 1 Human embryonic stem cell samples used in the KaryoL
hESC line Passage (p) Karyotype (G-banding)
H7.s14 a P30 46,XX[20]
H7.s6 a P128 47,XX,+1,der(6)t(6;17)(q27;q1)[
/47,XX,+1,der(6)t(6;17)(q27;q1
H7.s6 a P230 49,XXX,+add(1)(p3),der(6)t(6;1
H7.s6.ter a P125 47,XX,+add(1)(p1),der(6)t(6;17)
H9 a P25 46,XX[20]
H9 P35 46,XX[20]
H9 P38 46,XX[3×2]
H9 P99 47,XX,+12[15]
H9 P112 47,XX,+12[15]
HS401 a P53 46,XY[30]
HS293 a P60 Not determined
FES22 a P41 46, XY[11]
FES29 a P37 46,XY, add(13)(p1)[1]/46,XY[30
a Previously analyzed with karyotyping and Affymetrix SNP6.0 arraysrecurrent chromosomal aberrations in hESCs lines (Baker et al.,
2007; Laurent et al., 2011; Taapken et al., 2011; Spits et al.,
2008; Lefort et al., 2008). Selected sample material was used
to examine capacity of KaryoLite™ BoBs™ in the detection of
known abnormalities in hESCs and sensitivity to detect the
changes in karyotypically heterogeneous cell populations.
Altogether 12 samples (7 hESC lines), 7 normal and 6 abnormal,
including 2 lines with mosaic karyotypes, were studied with
KaryoLite™ BoBs™ assay. From each sample at least 100 ng of
DNA was used as a starting material for the karyotypic analysis.
The samples were processed according to the instructions
described in the KaryoLite™ BoBs™ manual (Product Number
4501–0010, Perkin Elmer, Turku, Finland). According to the
assay workflow (Supplementary Fig. 1), the sample DNA is
labeled with Biotin, purified and hybridized to beads with
complementary BAC probes. After washing and reporter
(streptavidin-PE) binding the fluorescent signals are measured
with Luminex instrument and results analyzed with BoBsoft™
analysis software (Perkin Elmer). In this study female and
male genomic DNA from the karyotypically normal hESC
lines were used as a reference. Alternatively, commercial
female and male reference DNA can be used. The BoBsoft™
depicts karyotypes as a ratio plots against female and male
reference signals of normal karyotype (either measured
from external DNA samples or calculated for each bead
from the normally behaving beads in the assay data). The
user defined threshold values for karyotypic changes are
generated by the BoBsoft data analysis software and are
multiples of standard deviation, calculated from beads
with ratios b2SD from 1.
As expected, the analysis results did not indicate any large
scale genomic abnormalities in the karyotypically normal hESC
lines (H7p30, H9p25, H9p35, H9p38, HS401p53, HS293p60 or
FES22p41) (Narva et al., 2010). For the abnormal cell lines
(H7p128, H7p230, H7 teratoma p125, H9p99 or H9p112) all the
large scale gains detected with karyotyping and or SNP6.0
arrays in the chromosomes 1, 12, 17, 20 or X were detected
also with KaryoLite™ BoBs™ assay (Fig. 1). Even the mosaic
isochromosome 20(q10) present in 5 of the 20 metaphases
(25%) of H7p128 line was detected as a deletion of telomeric
area of the p-arm. For the same sample previous SNP6.0 array
revealed gain of the p-arm and loss of q-arm. Interestingly,ite™ BoBs™ analysis.
Karyotyped (p) Laboratory
P38 P.W.A.
15]
),i(20)(q10)[5] P132 P.W.A.
7)(q27;q1),+20[30] P237 P.W.A.
(q27;q1),i(20)(q10)[30] P127 P.W.A.
P27 R.L.
P36 R.L.
P37 R.L.
P60 R.L.
P60 R.L.
P53 R.L.
R.L.
P42 T.O.
] P37 T.O.
(Narva et al., 2010).
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Figure 1 Karyotypic changes detected by KaryoLite™ BoBs™ assay in human embryonic stem cells in comparison to Affymetrix
SNP6.0 arrays or G-banding. In Fig. 1A (H7 line) and B (H9 line) are the abnormalities detected by KaryoLite™ BoBs™ assay (right panel)
in comparison to Affymetrix SNP6.0 arrays and/or Chromosome G-banding method (left panel). In the left panel the chromosomal
areas painted with red color indicate losses detected with Affymetrix SNP6.0 arrays, whereas blue indicates gains. In the right panel
the red and blue lines indicate chromosomal signal ratios against female (red) and male (blue) reference DNA with normal karyotypes
as detected by KaryoLite™ BoBs™ assay. For the normal chromosomes both the signals calculated against male and female references
should reside inside the reference area around value 1, whereas for the abnormal karyotype both signals should be outside the
reference area. In Fig. 1C are the representative cytogenetic data for H9 line with karyotype 47,XX,+12.
194 R.J. Lund et al.both KaryoLite™ BoBs™ and Affymetrix SNP6.0 arrays detected
gain of Chromosome 10 in the H7p230 sample, which was not
detected by conventional G-banding method. Similarly to
SNP6.0 arrays, none of the balanced translocations detected
with G-banding were detected by bead based system. To
examine the detection threshold for mosaic karyotypes, H9
cells with trisomy of chromosome 12 were mixed withkaryotypically normal cells in 0%, 20%, 30%, 50% and 100%
proportions. The results show that when the proportion of
karyotypically abnormal cells is at least ≥30% within the cell
population they can be detected by the KaryoLite™ BoBs™
(Fig. 2). Thus, the mosaicism of cell line FES29p37, previously
reportedwith the karyotype 46,XY, add(13)(p1)[1]/46,XY[30],
was not detected by either KaryoLite™ BoBs™ or previously by
Figure 2 Detection threshold of mosaic trisomy 12. Human
H9p35 embryonic stem cells with normal karyotype were pooled
in different proportions with H9p112 karyotypically abnormal
cells carrying trisomy of chromosome 12 as indicated in the
figure. The karyotypes were analyzed with Karyolite BoBs assay
to estimate the threshold for detection of mosaic chromosomal
abnormalities.
195High-Throughput Karyotyping of Human Pluripotent Stem CellsSNP6.0 arrays. In conclusion, the data obtained with bead
based system are in good concordance with the previous
analysis performed using G-banding method and Affymetrix
SNP6.0 arrays.
These results highlight that the novel KaryoLite™ BoBs™
assay provides a valuable tool for routine screening of the
recurrent and random chromosomal abnormalities observed in
hESC lines. The method is most likely to be applicable for
monitoring of iPSC lines as well, although these were not
included in this study. The analysis with KaryoLite™ BoBs™ can
be carried out in a 96-well format enabling scaling up the
sample numbers. The data analysis interface is simple to use
and the results are clear and easy to interpret. The sensitivity
of the method may also enable detection of large scale
karyotypic aberrations in mosaic populations. The benefit of
the method in comparison to conventional karyotyping also
includes examination of the whole cell population rather than
fraction of the cells (typically b50 mitosis) providing improved
representation of the genomic integrity of the whole cell
population (Supplementary Table 1). Themethod is not suitable
for detecting balanced translocations or with current probe
selection sensitive enough for small scale changes. However,
most of the recurrent genomic changes in pluripotent cells
involve whole chromosomes or chromosome arms (Baker et al.,
2007; Laurent et al., 2011; Taapken et al., 2011; Spits et al.,
2008; Lefort et al., 2008; The International Stem Cell Initiative
et al., 2011). Also for detection of low level of mosaicisms
the conventional G-banding is more sensitive method. For
important samples a thorough analysis utilizing more sensitive
methods detecting balanced rearrangement and also small
copy number variations is recommended. In conclusion, the
novel method described here provides rapid, high-throughputand cost-efficient tool for frequent monitoring and screening
of the genomic integrity of stem cell cultures.
Supplementary related to this article can be found online
at http://dx.doi.org/10.1016/j.scr.2012.06.008.
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